Background: Chronic inflammation and dyslipidemia are part of type 2 diabetes mellitus (T2DM) associated cardiovascular complications. Interleukin-6 (IL-6) and interleukin-17 (IL-17) are pro-inflammatory cytokines associated with metabolic disturbances. Objectives: To evaluate the levels of IL-6 and IL-17 in serum of T2DM patients, and to explore their association with lipid profile parameters. Methods: A case-control study with 100 individuals was carried out including T2DM patients (n=50) and healthy group as a control group (n=50). Demographic information was collected such as age, sex and body mass index (BMI). The concentrations of IL-6 and IL-17 were detected by enzyme-linked immunosorbent assay (ELISA). Serum lipid profile, including total cholesterol (TC), triglycerides (TG), low density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein-cholesterol (HDL-C) was evaluated. The data was analyzed using SPSS version 26.0 control-group software. Results: The T2DM patients had significantly higher level of IL-6 (48.3 ± 12.4 pg/mL vs. 18.2±5.6 pg/mL, p<0.001) and of IL-17 (35.7±9.8 pg/mL vs 12.4±4.2 pg/ml, p<0.l)) than control subjects. T2DM patients had a higher incidence of lipid abnormalities, such as increased TC, TG and LDL-C levels, and decreased HDL-C level. IL-6 was positively correlated with TG (r=0.64, p<0.001), TC (r=0.52, p<0.001), and LDL-C (r=0.48, p<0.001). IL-17 significantly correlated with TG (r=0.58, p<0.001) and LDL-C (r=0.44, p<0.01). Both cytokines were inversely associated with HDL-C. Conclusion: Increased levels of IL-6 and IL-17 in T2DM patients are significantly associated with dyslipidemia, supporting their potential value as inflammatory biomarkers for cardiovascular risk analysis in diabetic population.